Answers are grounded in this paper and cite their sources.
The development of therapeutic molecules that specifically recognize cancer cells has reinforced the hope of developing patient-tailored treatments. By combining greater efficacy with selective targeting of cancer cells, treatments aim to inhibit tumor cell growth and invasion while sparing the surrounding normal cells, thus reducing the adverse cytotoxic side effects caused by conventional chemotherapy.1 To date, monoclonal antibodies (mAbs) represent the largest class of therapeutic agent for the specific recognition of cell surface antigens.
No takes yet. Share an insight, caveat, or question.
Vittorio de Franciscis (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: